Search Results - David Floch

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody

    Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody by Abhijit Chakraborty, Stacey Tannenbaum, Christiane Rordorf, Philip J. Lowe, David Floch, Hermann Gram, Sandip Kumar Roy

    Published 2012
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Pharmacokinetics, pharmacodynamics and safety of <scp>QGE</scp>031 (ligelizumab), a novel high‐affinity anti‐IgE antibody, in atopic subjects

    Pharmacokinetics, pharmacodynamics and safety of <scp>QGE</scp>031 (ligelizumab), a novel high‐affinity anti‐IgE antibody, in atopic subjects by Jonathan Arnold A. P., I. Bottoli, Andrej Skerjanec, David Floch, A. Groenewegen, Suzanne Maahs, Claire Owen, Ieuan Jones, Philip J. Lowe

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study

    Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study by Benjamin A. Fisher, Antónia Szántó, Wan‐Fai Ng, Stefano Bombardieri, Maximilian Posch, Athena Papas, Arwa M. Farag, Thomas Daikeler, Bettina Bannert, Diego Kyburz, Alan Kivitz, Steven E. Carsons, David Isenberg, Francesca Barone, Simon Bowman, Pascal Espié, David Floch, Cyrielle Dupuy, Xiaohui Ren, P. Faerber, A. Wright, Hans Hockey, Michael Rotte, Julie Milojevic, Alexandre Avraméas, Marie‐Anne Valentin, James S. Rush, P Gergely

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: